Image courtesy of University of Tennessee Medical Center, Knoxville, Tennessee, USA.
Cervical cancer is the fourth most common cancer in women.1 PET/CT in addition with Fludeoxyglucose F18 injection (18F FDG) can be used together to promote the use of PET/CT for personalized treatment triage and planning, which could possibly impact therapy management and follow-up for patients with cervical cancer. Download the white paper below to learn more about the role of FDG PET/CT and cervical cancer, in addition to more information on national cancer guidelines and reimbursement policies.